SCH 62373

Drug Profile

SCH 62373

Latest Information Update: 18 Dec 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Schering-Plough
  • Class Antiasthmatics; Antirheumatics; Piperazines
  • Mechanism of Action Neurokinin 1 antagonists; Neurokinin 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma

Most Recent Events

  • 18 Dec 2003 No development reported - Preclinical for Asthma in USA (unspecified route)
  • 30 Apr 2001 New profile
  • 30 Apr 2001 Preclinical development for Asthma in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top